Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
NCT ID: NCT04806243
Last Updated: 2021-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
69 participants
INTERVENTIONAL
2021-05-06
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
NCT04826406
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
NCT04443309
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
NCT05003700
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
NCT05048017
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
NCT06280105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This research is a single-center trials phase II second-line, single arm, explore the clinical outcome of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carelizumab Combined With Regorafenib arm
Regorafenib Pill&Camrelizumab
Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regorafenib Pill&Camrelizumab
Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFEC-2021-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.